Inventor · disambiguated record
Guillermo A. Morales
Also filed as: MORALES GUILLERMO · MORALES GUILLERMO A
9 granted patents·2 pending applications·74 citations·filing 1997–2021
87Inventor score
Top patents by PatentIndex Score
11 records- 0193US9505780B2Thienopyranones as kinase and epigenetic inhibitorsSIGNALRX PHARMACEUTICALS INC·Filed 2015·Granted Nov 29, 2016·9 cites·2 claims
- 0291US10308662B2Thienopyranones as kinase and epigenetic inhibitorsSIGNALRX PHARMACEUTICALS INC·Filed 2017·Granted Jun 4, 2019·6 cites·11 claims
- 0389US9981983B2Thienopyranones as kinase inhibitorsSIGNALRX PHARMACEUTICALS INC·Filed 2016·Granted May 29, 2018·5 cites·4 claims
- 0489US9550790B2Thienopyranones as kinase inhibitorsSIGNALRX PHARMACEUTICALS INC·Filed 2013·Granted Jan 24, 2017·8 cites·1 claims
- 0588US10174032B2Heterocyclic compound classes for signaling modulationSIGNALRX PHARMACEUTICALS INC·Filed 2015·Granted Jan 8, 2019·6 cites·2 claims
- 0681US8557807B2Thienopyranones as kinase inhibitorsMORALES GUILLERMO A·Filed 2009·Granted Oct 15, 2013·13 cites·6 claims
- 0779US11472814B2Thienopyranones and furanopyranones as checkpoint inhibitors and modulators of anti-tumor immunitySIGNALRX PHARMACEUTICALS INC·Filed 2018·Granted Oct 18, 2022·3 cites·18 claims
- 0875US6028216AAsymmetric syntheses and intermediates for preparing enantiomer-enriched hydroxyphosphinyl derivativesGUILFORD PHARM INC·Filed 1997·Granted Feb 22, 2000·24 cites·13 claims
- 0958US2017101418A1Thienopyranones as Kinase and Epigenetic InhibitorsSIGNALRX PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 1057US11760762B2Thienopyranones and furanopyranones as kinase, bromodomain, and checkpoint inhibitorsSIGNALRX PHARMACEUTICALS INC·Filed 2018·Granted Sep 19, 2023·0 cites·6 claims
- 1154US2023165873A1Methods of Use for Single Molecule Compounds Providing Multi-Target Inhibition to Treat Covid 19SIGNALRX PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Guillermo A. Morales files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →